Cargando…

Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia

Detalles Bibliográficos
Autores principales:	Schuessler‐Lenz, Martina, Enzmann, Harald, Vamvakas, Spiros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027974/ https://www.ncbi.nlm.nih.gov/pubmed/31705534 http://dx.doi.org/10.1002/cpt.1639

Ejemplares similares

Zynteglo: Betibeglogene autotemcel – An innovative therapy for β- thalassemia patients
por: Asghar, Adam Ali, et al.
Publicado: (2022)

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
por: Delgado, Julio, et al.
Publicado: (2021)

PRAC meeting highlights July 2021: Zynteglo and COVID-19 vaccines
Publicado: (2021)

Promoting Safe Early Clinical Research of Novel Drug Candidates: A European Union Regulatory Perspective
por: Ponzano, Stefano, et al.
Publicado: (2017)

The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
por: Cavaleri, Marco, et al.
Publicado: (2021)

European Medicines Agency Conflicts With the European Food Safety Authority (EFSA) on Bisphenol A Regulation
por: Zoeller, R Thomas, et al.
Publicado: (2023)

Biomarker Qualification at the European Medicines Agency: A Look Under the Hood
por: Berman, Steven, et al.
Publicado: (2022)

The Added Value of Patient Engagement in Early Dialogue at EMA: Scientific Advice as a Case Study
por: Murphy, Aisling, et al.
Publicado: (2022)

The European Medicines Agency's approval of new medicines for type 2 diabetes
por: Blind, Eberhard, et al.
Publicado: (2018)

Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation
por: Eichler, Hans‐Georg, et al.
Publicado: (2019)

Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency
por: Elsäßer, Amelie, et al.
Publicado: (2014)

Clinical Trials for COVID‐19: Can we Better Use the Short Window of Opportunity?
por: Eichler, Hans‐Georg, et al.
Publicado: (2020)

Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective
por: Manolis, Efthymios, et al.
Publicado: (2023)

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
por: Alsina, Maria, et al.
Publicado: (2019)

Improve how science advice is provided to governments by learning from “experts in expert advice”
por: Pielke, Roger
Publicado: (2023)

Thalassemia and Venous Thromboembolism
por: Succar, Julien, et al.
Publicado: (2011)

Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency
por: Collignon, Olivier, et al.
Publicado: (2018)

Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency
por: Maliepaard, Marc, et al.
Publicado: (2022)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
por: Orellana García, Laura Patricia, et al.
Publicado: (2021)

Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
por: Cherla, Avi, et al.
Publicado: (2022)

The Use of Remote Monitoring Technologies: A Review of Recent Regulatory Scientific Advices, Qualification Opinions, and Qualification Advices Issued by the European Medicines Agency
por: Dekker, Marieke J. H. J., et al.
Publicado: (2021)

Current european regulatory perspectives on insulin analogues
por: Enzmann, Harald G, et al.
Publicado: (2011)

Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021
por: Ciani, Oriana, et al.
Publicado: (2023)

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
por: Delgado, Julio, et al.
Publicado: (2021)

Beta-thalassemia
por: Galanello, Renzo, et al.
Publicado: (2010)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Advice on COVID-19 vaccines approved in UK by MHRA
Publicado: (2021)

Feds update immunization advice with Moderna vaccine approval
por: Vogel, Lauren
Publicado: (2021)

European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer
por: Stanel, Stefan Cristian, et al.
Publicado: (2017)

Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022
por: Ciani, Oriana, et al.
Publicado: (2023)

Regulatory agencies issue advice on use of NSAIDs for COVID-19
Publicado: (2020)

The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports
por: Erhel, Florian, et al.
Publicado: (2020)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Delgado, Julio, et al.
Publicado: (2021)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

Challenges and advice for MD/PhD applicants who are underrepresented in medicine
por: Bannerman, Carl, et al.
Publicado: (2020)

The Case of Deborah Rice: Who Is the Environmental Protection Agency Protecting?
por: Needleman, Herbert L
Publicado: (2008)

Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications
por: Kwon, Hye-Young, et al.
Publicado: (2018)

Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada
por: Lythgoe, Mark P., et al.
Publicado: (2021)

Good advice for endothelial cells: Get in line, relax tension, and go with the flow
por: Kaunas, Roland
Publicado: (2020)

Perspective: A Conceptual Framework for Adaptive Personalized Nutrition Advice Systems (APNASs)
por: Renner, Britta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u3hdmo0tbadpdphgld2qk37vu0